Parallel Arm Trial of AD109 and AD504 In Patients With OSA
Trial details
- Registry ID
- NCT05071612
- Phase
- Phase 2
The FDA approved Atomoxetine Hydrochloride on 26 Nov 2002.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Parallel Arm Trial of AD109 and AD504 In Patients With OSANCT05071612 | Apnimed | Phase 2 | Completed | 2022-07-20Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2002-11-26Day | Atomoxetine Hydrochloride | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA021411", "applicant_as_listed_by_fda": "LILLY", "brand_names": ["STRATTERA"], "active_ingredients": ["ATOMOXETINE HYDROCHLORIDE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20021126", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |